RianCorp

RianCorp RianCorp focus on medical laser products in the field of Low Level Laser Therapy. The LTU-904 is the ONLY laser device cleared by FDA for lymphedema treatment.

The RianCorp LTU-904 laser has been trialled in the first ever randomised double blind clinical trial testing the effects of LLLT on lymphoedema. LOW LEVEL LASER THERAPY (LLLT) IS EFFECTIVE IN TREATING:
• Lymphoedema
• Slow healing skin wounds
• Fibrous lesions
• Sprained & strained ligaments
• Tendon injuries
• Muscle soreness

ADVANTAGES OF USING THE LTU-904 LASER:
• Painless & often immediate analgesic effect
• Shortened recovery time with rapid reduction of swelling & inflammation
• Non-invasive & patient friendly
• Class 1 laser & therefore eye-safe for patients & clinicians

~~~~~~~~~~~~~

The LTU-904 laser is the only low level laser manufactured in Australia and registered with the Australian Therapeutic Goods Administration.

~~~~~~~~~~~~~

The American Food and Drug Administration has cleared the Riancorp LTU-904 laser therapy units as a tool to be used in the treatment of post mastectomy lymphedema.

03/10/2023

Dont forget to bring your laser to the NLN for calibration. We are offering special calibration pricing at the conference.

15/01/2022

Interesting news release about the use of Laser for Parkinson's disease on the News this week.

Same wavelength as our laser!
We offer unit rental if anyone wants to try.

21/05/2021

Great to see everyone at the ALA Conference on the weekend. So wonderful to finally get face to face!

LOW LEVEL LASER TO HELP COVID PATIENTSThere have been a couple of reports about the use of laser for COVID patients. Whe...
22/04/2021

LOW LEVEL LASER TO HELP COVID PATIENTS

There have been a couple of reports about the use of laser for COVID patients. When you think about it, our LTU-904 has been used for inflammation and fibrotic congestion for more than 20 years, so it's not surprising that it may help COVID patients who are suffering from symptoms related to inflammation in the body.

One article from the USA reports the use of a 905nm laser, which is the same wavelength as the LTU-904. https://www.lowellsun.com/2021/04/10/local-laser-therapy-study-yields-promising-results-for-coronavirus-patients/

The hospital involved is now conducting a bigger study, under hospital ethics control. We look forward to seeing the outcomes of the study.

LOWELL — As an orthopedic surgeon, Dr. Scott Sigman might be the last person one would expect to lead a study centered around treating the lungs of COVID-19 patients. But to Sigman, who has b…

06/04/2021

We will be at the ALA Symposium in May.

Drop off your laser to Ann at the RianCorp booth for calibration.

23/03/2020

RianCorp and our service centre are currently operating as normal.

Keep an eye on our page for the announcement of a date/times for our first ever online laser presentations! There will be no cost to join us.

We hope you all stay safe and well.

17/03/2020

If you have lymphoedema (or manage certain chronic pain conditions) and are unable to travel for treatment - enquire now about our monthly rental of the LTU-904 laser for home-use. Email Helen at: sales@riancorp.com

02/12/2019

As a reminder - our service centre is closed over Christmas and we send our testing equipment away for its annual servicing from mid-Dec to mid-Jan. No laser servicing is available during this period.

02/12/2019

LOW-LEVEL LASER THERAPY FOR FIBROMYALGIA: A Systematic Review and Meta-Analysis
Yeh SW, Hong CH, Shih MC, Tam KW, Huang YH, Kuan YC.

Abstract

BACKGROUND:
Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness. Low-level laser therapy (LLLT), an emerging nonpharmacological treatment, has been used for relieving musculoskeletal or neuropathic pain.

OBJECTIVE:
The objective of this review and meta-analysis was to determine the efficacy of LLLT on patients with fibromyalgia.

STUDY DESIGN:
This study involved systematic review and quantitative meta-analysis of published randomized controlled trials (RCTs).

SETTING:
This study examined all RCTs evaluating the effect of LLLT on fibromyalgia.

METHODS:
We performed a systematic review and meta-analysis of RCTs evaluating the effect of LLLT on patients with fibromyalgia. PubMed, EMBASE, and the Cochrane Library were searched for articles published before August 2018. RCTs meeting our selection criteria were included. The methodological quality of the RCTs was evaluated according to the Cochrane risk-for-bias method. Review Manager version 5.3 was used to perform the meta-analysis. The primary outcomes were the total scores on the Fibromyalgia Impact Questionnaire (FIQ), pain severity, and number of tender points. The secondary outcomes were changes in fatigue, stiffness, anxiety, and depression. Standardized mean difference (SMD), 95% confidence intervals (CI), and P values were calculated for outcome analysis.

RESULTS:
We identified 9 RCTs that included 325 fibromyalgia patients undergoing LLLT or placebo laser treatment with or without an exercise program. The meta-analysis showed that patients receiving LLLT demonstrated significantly greater improvement in their FIQ scores (SMD: 1.16; 95% CI, 0.64-1.69), pain severity (SMD: 1.18; 95% CI, 0.82-1.54), number of tender points (SMD: 1.01; 95% CI, 0.49-1.52), fatigue (SMD: 1.4; 95% CI, 0.96-1.84), stiffness (SMD: 0.92; 95% CI, 0.36-1.48), depression (SMD: 1.46; 95% CI, 0.93-2.00), and anxiety (SMD: 1.46; 95% CI, 0.45-2.47) than those receiving placebo laser. Furthermore, when compared with the standardized exercise program alone, LLLT plus the standardized exercise program provided no extra advantage in the relief of symptoms. On the other hand, the results of the only RCT using combined LLLT/LED phototherapy showed significant improvement in most outcomes except for depression when compared to placebo. When compared with pure exercise therapy, combined LLLT/LED phototherapy plus exercise therapy had additional benefits in reducing the severity of pain, number of tender points, and fatigue.

LIMITATIONS:
There were some limitations in this review, mostly because of the low-to-middle methodological quality of the selected studies; for example, there was no clear allocation process and only patients were blinded in most studies. In addition, one study used per-protocol analysis with a 20% loss to follow-up. On the other hand, the differences in laser types, energy sources, exposure times, and associated medication status in these studies may have resulted in some heterogeneity.

CONCLUSIONS:
Our results provided the most up-to-date and relevant evidence regarding the effects of LLLT in fibromyalgia. LLLT is an effective, safe, and well-tolerated treatment for fibromyalgia

Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/31151332

Full article here: https://www.painphysicianjournal.com/current/pdf?article=NjMwNA%3D%3D&journal=120

31/07/2019

About ten percent of all cancer patients suffer from lymphoedema, which produces swelling in the legs, arms and breasts. The ETH start-up Dicronis has developed an instrument for simple and early diag

15/05/2019

Dont forget to bring your laser to Sydney for calibration at the ALA

Address

2 331 Seaview Road, Henley Beach
Melbourne, VIC
5022

Alerts

Be the first to know and let us send you an email when RianCorp posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to RianCorp:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram